Tonabersat

托那博沙

Report date: 2024/06/21 13:48:21
NMEFirst In Class

Base Information

Drug NameTonabersat
Drug Alias NametonabersattonabersatetonabersatumXiflamUSL-260 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGap junction alpha-1 protein inhibitors
TargetsGap junction alpha-1 protein
Therapy Area/IndicationsDiabetic macular oedemaPost-Acute COVID-19 SyndromeMigraine without Aura +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth AfricaHungary +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Inc
China Registration ClassN/A

Develop Information

Active CompaniesProximagen Group plcInflammx Therapeutics IncJaeb Center For Health Research Inc
Inactive CompaniesMinster Research Ltd
Active IndicationsDiabetic macular oedemaPost-Acute COVID-19 Syndrome
Inactive IndicationsMigraine without AuraMigraine with Aura

Other Information

ATC CodeN/A
Related LinksDrugBank